Document Detail

99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy?
MedLine Citation:
PMID:  12552335     Owner:  NLM     Status:  MEDLINE    
Several years ago technetium-99m tetrofosmin was reported to localise parathyroid adenomas. The aim of this study was to compare the sensitivity of this radiopharmaceutical with that of (99m)Tc-sestamibi using a double-phase parathyroid scintigraphy protocol. Scans of 12 patients were evaluated visually and lesion to thyroid ratios were calculated. Nine of the patients were subsequently operated on; a total of eight parathyroid adenomas or hyperplastic glands were histologically confirmed in seven of the patients, while in one patient a parathyroid carcinoma was histologically proven. All of these patients had positive (99m)Tc-sestamibi scintigrams, whereas only two (99m)Tc-tetrofosmin scintigrams were positive. With (99m)Tc-sestamibi there was a significant increase in the lesion to thyroid ratio from 10 min to 90 min and 150 min p.i. which was not seen on scintigraphy with (99m)Tc-tetrofosmin. This makes (99m)Tc-tetrofosmin less suitable for double-phase parathyroid scintigraphy.
Alida C Fröberg; Roelf Valkema; H Jaap Bonjer; Eric P Krenning
Related Documents :
17288745 - Plasma homocysteine levels in patients treated with levodopa: motor and cognitive assoc...
16388525 - Prevalence and risk factors for primary hyperparathyroidism in hyperthyroid patients.
1272325 - Parathyroid autotransplantation in primary parathyroid hyperplasia.
17369135 - Postresection parathyroid hormone and parathyroid hormone decline accurately predict hy...
20846585 - Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patien...
8281475 - Pseudoaneurysm after bentall repair: magnetic resonance imaging assessment.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article     Date:  2002-11-23
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  30     ISSN:  1619-7070     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2003 Feb 
Date Detail:
Created Date:  2003-01-28     Completed Date:  2003-09-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  193-6     Citation Subset:  IM    
Department of Nuclear Medicine, Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenoma / complications,  pathology,  radionuclide imaging*
Hyperparathyroidism / etiology,  pathology,  radionuclide imaging
Middle Aged
Organophosphorus Compounds / diagnostic use*
Organotechnetium Compounds / diagnostic use*
Parathyroid Glands / pathology,  radionuclide imaging
Parathyroid Neoplasms / complications,  pathology,  radionuclide imaging*
Predictive Value of Tests
Radiopharmaceuticals / diagnostic use
Reproducibility of Results
Sensitivity and Specificity
Single-Blind Method
Technetium Tc 99m Sestamibi / diagnostic use*
Reg. No./Substance:
0/Organophosphorus Compounds; 0/Organotechnetium Compounds; 0/Radiopharmaceuticals; 0/technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane; 109581-73-9/Technetium Tc 99m Sestamibi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quantitative cerebral H2(15)O perfusion PET without arterial blood sampling, a method based on washo...
Next Document:  Diagnostic and prognostic value of 99mTc-tetrofosmin scintigraphy in maxillofacial flaps.